The company reports positive results from the dose escalation Phase I trial, showing significant tumor shrinkage and durable responses to DSP107 in combination with anti-PD-L1 in patients with microsatellite stable colorectal cancer (MSS-CRC).
MSS-CRC is considered a ‘cold’ tumor that usually does not respond efficiently to immunotherapy.
